BIIB022

DRUG2 trials

Sponsors

Biogen

Conditions

Hepatocellular CarcinomaSolid Tumors

Phase 1

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

CompletedNCT00555724

BiogenSolid Tumors

Start: 2008-01-31End: 2010-07-31Updated: 2017-01-09

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

CompletedNCT00956436

BiogenHepatocellular Carcinoma

Start: 2009-08-31End: 2011-04-30Updated: 2013-09-16